Search Results - "Grimes, Imogene"

Risk-Based Source Data Verification Approaches: Pros and Cons by Tantsyura, Vadim, Grimes, Imogene, Mitchel, Jules, Fendt, Kaye, Sirichenko, Sergiy, Waters, Joel, Crowe, Jim, Tardiff, Barbara

“…The high cost of source data verification (SDV), particularly in large trials, has made it a target of scrutiny over the last decade. In addition, the positive…”
Get full text

Effect of TTP488 in patients with mild to moderate Alzheimer's disease by Burstein, Aaron H, Grimes, Imogene, Galasko, Douglas R, Aisen, Paul S, Sabbagh, Marwan, Mjalli, Adnan M M

“…TTP488, an antagonist at the Receptor for Advanced Glycation End products, was evaluated as a potential treatment for patients with mild-to-moderate…”
Get full text

P3‐315: Ttp488 path to registration: Leveraging enrichment strategies by Sabbagh, Marwan N., Burstein, Aaron, Grimes, Imogene, Valcarce, Carmen, Doody, Rachelle S., Sano, Mary, Schneider, Lon S., Galasko, Douglas, Rose, Eric

Get full text

O4‐09‐03: Ttp488: From futile to fast track by Sabbagh, Marwan N., Burstein, Aaron, Grimes, Imogene, Valcarce, Carmen, Rose, Eric, Doody, Rachelle S., Sano, Mary, Schneider, Lon S., Galasko, Douglas

Get full text

Ttp488 path to registration: Leveraging enrichment strategies by Sabbagh, Marwan N, Burstein, Aaron, Grimes, Imogene, Valcarce, Carmen, Doody, Rachelle S, Sano, Mary, Schneider, Lon S, Galasko, Douglas, Rose, Eric

Get full text

Ttp488: From futile to fast track by Sabbagh, Marwan N, Burstein, Aaron, Grimes, Imogene, Valcarce, Carmen, Rose, Eric, Doody, Rachelle S, Sano, Mary, Schneider, Lon S, Galasko, Douglas

Get full text

P1–332: Evaluation of the relationship between TTP488 plasma concentrations and changes in ADAS‐cog relative to placebo by Burstein, Aaron, Galasko, Douglas, Aisen, Paul, Thomas, Ronald, Grimes, Imogene, Clark, David J., Mjalli, Adnan, Orlande, Cesare

Get full text

Evaluation of the relationship between TTP488 plasma concentrations and changes in ADAS-cog relative to placebo by Burstein, Aaron, Galasko, Douglas, Aisen, Paul, Thomas, Ronald, Grimes, Imogene, Clark, David J, Mjalli, Adnan, Orlande, Cesare

Get full text

Rabeprazole: Pharmacokinetics in patients with stable, compensated cirrhosis by Hoyumpa, Anastacio M., Trevino-Alanis, Hector, Grimes, Imogene, Humphries, Thomas J.

“…This single-center, open-label study was undertaken to compare the tolerability and pharmacokinetic profiles of rabeprazole, a new proton-pump inhibitor (PPI),…”
Get full text

Rabeprazole: Pharmacokinetics and Tolerability in Patients with Stable, End-Stage Renal Failure by Keane, William F., Swan, Suzanne K., Grimes, Imogene, Humphries, Thomas J.

“…The authors compare the pharmacokinetic profiles, safety, and tolerability of rabeprazole, a new proton pump inhibitor (PPI), in healthy volunteers and in…”
Get full text

Cost-Effective Approach to Managing Laboratory Reference Ranges for Local Laboratories in Clinical Research by Tantsyura, Vadim, Grimes, Imogene, Mitchel, Jules, Sirichenko, Sergiy, Crowe, Jim, Viola, Deborah

“…The use of a single central laboratory with universal references ranges is not always a viable option in clinical studies; examples are oncology studies where…”
Get full text

Rabeprazole: Pharmacokinetics and Tolerability in Patients with Stable, End-Stage Renal Failure by Keane, William F, Swan, Suzanne K, Grimes, Imogene, Humphries, Thomas J

“…The authors compare the pharmacokinetic profiles, safety, and tolerability of rabeprazole, a new proton pump inhibitor (PPI), in healthy volunteers and in…”
Get full text